title: Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
abstract: Summary. In haemophilia patients with inhibitor, elective orthopaedic surgery is usually performed under recombinant activated factor VII (rFVIIa). We report here the case of a severe haemophilia A patient with a high inhibitor who needed a bilateral total knee arthroplasty. Recombinant FVIIa was previously shown to be ineffective for the treatment of muscle and joint bleedings, and he had a history of excessive postoperative bleeding under activated prothrombin complex concentrate (APCC). Thrombin generation test (TGT) was used to assess the efficacy of Factor Eight Inhibitor Bypassing Activity (FEIBA). Insufficient correction of thrombin-generating capacity was observed after administration of 75 U kg(-1) FEIBA. In a multidisciplinary environment, a bilateral total knee arthroplasty was performed using a protocol combining immunoadsorption of inhibitors preoperatively associated with FVIII replacement during a first phase followed by FEIBA when the inhibitor reappeared. To our knowledge this is the first direct application of TGT in the management of haemophilia patients with inhibitor, which indicated that a sequential use of immunoadsorption, FVIII and FEIBA was the most appropriate treatment to perform this major elective surgery. This case demonstrates that this combined protocol can be safely used to cover major surgery in inhibitor patients. In addition, it also suggests that TGT may have a major contribution in the decision-making process of the most adapted therapy for the treatment of such high-risk patients.
authors.affiliation: Centre Régional de Traitement de l'Hémophilie, Hôpital Edouard Herriot, Lyon, France. ydargaud@aol.com
authors.forename: Y
authors.initials: Y
authors.lastname: Dargaud
authors.forename: A
authors.initials: A
authors.lastname: Lienhart
authors.forename: S
authors.initials: S
authors.lastname: Meunier
authors.forename: O
authors.initials: O
authors.lastname: Hequet
authors.forename: H
authors.initials: H
authors.lastname: Chavanne
authors.forename: V
authors.initials: V
authors.lastname: Chamouard
authors.forename: S
authors.initials: S
authors.lastname: Marin
authors.forename: C
authors.initials: C
authors.lastname: Negrier
mesh_terms: D000328:Adult; D019645:Arthroplasty, Replacement, Knee; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D001780:Blood Coagulation Tests / Q000379:methods; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy*; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa